Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar stovkey1highdiv (< 20) Submitted: 3/25/2011 4:18:42 PM : Outperform Start Price: $55.49 CELG Score: +23.77

key03, no dividend, neutral

Featured Broker Partners


Advertisement